ロード中...
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
OBJECTIVE: The Escala Study evidenced that the administration of glatiramer acetate for relapsing-remitting multiple sclerosis improved the spasticity of patients previously treated with interferon-β. However, whether such an improvement was translated into cost savings remained unclear. We therefor...
保存先:
| 出版年: | Health Econ Rev |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4608957/ https://ncbi.nlm.nih.gov/pubmed/26475277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13561-015-0066-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|